Lithera Announces Notice of Allowance for Key United States Patent Application for LIPO-202, Its Novel Product for Localized Fat Reduction SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering formulations and...

Lithera, Inc. Completes $20.6 Million Equity Financing SAN DIEGO, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. Additional investment may provide the Company with up to a...

Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)...

Lithera Obtains Orphan Drug Product Designation for LIPO-102 SAN DIEGO, Calif., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the receipt of Orphan Drug Product Designation for LIPO-102 for the treatment of symptomatic exophthalmos associated...

Lithera Successfully Completes Phase I Clinical Trial of LIPO-102 SAN DIEGO, Feb. 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the successful completion of a three-part Phase I clinical trial of LIPO-102 being developed for the treatment of...